John Gever is a freelance writer who contributes to MedPage Today. His articles cover a wide range of topics in the medical field, including studies on various diseases, treatment options, and healthcare disparities. John's writing aims to provide accurate and informative insights into the latest developments in medicine and healthcare.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
John Gever's coverage primarily focuses on medical research related to autoimmune diseases such as rheumatoid arthritis, psoriatic arthritis, and osteoarthritis. He heavily relies on data in his articles. Given the nature of his work, he would likely be interested in hearing from experts who can provide insights into new research findings or clinical data related to autoimmune diseases and their treatment.
As a journalist covering scientific and healthcare topics with a strong emphasis on citing data, John may prefer sources who are actively involved in medical research or have access to significant clinical data that can support the points being made. Additionally, given the technical nature of his reporting, pitches should be tailored towards providing detailed scientific insights rather than general healthcare trends.
This information evolves through artificial intelligence and human feedback. Improve this profile .
— Carefully structured run-walk program proves mettle in small trial
— British study tested collagenase injections against fasciotomy for hand contractures
By: John Gever
— Findings from new study raise the bar Real Chinese acupuncture was more effective than a sham version for treating sciatica stemming from herniated spinal disks in a randomized trial conducted in China.
— But Japanese study suggests losses need to be substantial Japanese people with hyperuricemia saw some reductions in urate levels when they
— European registry analysis brings surprises along with the expected
Taking a page from HIV medicine
— Treatment patterns shift as new products come on board Use of conventional synthetic drugs to treat juvenile idiopathic arthritis (JIA) fell
— Looks like FDA blew the call on selective JAK1 inhibitor Filgotinib, the rheumatoid arthritis (RA) oral drug that never made it to the
— Study: It's not deprivation per se, but intervening factors that go with it
— Trial finds conservative approach inferior to joint replacement
(833) 317-6278 
